Recommended Chemotherapy Regimens for Breast Cancer
HER2-Positive Disease
For HER2-positive breast cancer, the preferred first-line regimen is trastuzumab + pertuzumab + taxane (docetaxel or paclitaxel), with trastuzumab continued for 1 year total duration. 1, 2
First-Line Treatment (Adjuvant/Neoadjuvant)
Preferred regimens:
AC → Paclitaxel + Trastuzumab ± Pertuzumab 3, 4
- Doxorubicin 60 mg/m² IV + Cyclophosphamide 600 mg/m² IV every 21 days × 4 cycles
- Followed by Paclitaxel 80 mg/m² IV weekly × 12 weeks
- With Trastuzumab 4 mg/kg loading, then 2 mg/kg weekly (or 8 mg/kg loading, then 6 mg/kg every 3 weeks)
- Continue trastuzumab to complete 1 year total
- Pertuzumab can be added for T2 or N1 disease 3
TCH ± Pertuzumab (anthracycline-free option) 3, 4
- Docetaxel 75 mg/m² + Carboplatin AUC 6 + Trastuzumab every 21 days × 6 cycles
- Preferred for patients with cardiac concerns due to lower cardiotoxicity 4
Critical sequencing: Trastuzumab should be given concurrently with taxane, NOT with anthracycline, due to significant cardiac toxicity risk 5, 4. Cardiac monitoring required at baseline, 3,6, and 9 months 5.
Metastatic/Advanced HER2-Positive Disease
First-line: Trastuzumab + Pertuzumab + Taxane 1, 2
- Pertuzumab 840 mg IV loading, then 420 mg every 21 days
- Trastuzumab 8 mg/kg loading, then 6 mg/kg every 21 days
- Docetaxel 75-100 mg/m² every 21 days OR Paclitaxel 80 mg/m² weekly 6
Second-line: Trastuzumab emtansine (T-DM1) 3.6 mg/kg IV every 21 days if progression on first-line 1, 2
Updated second-line (2022): Trastuzumab deruxtecan (T-Dxd) is now preferred over T-DM1 as second-line treatment 2
Third-line and beyond: 1
- Lapatinib 1250 mg PO daily + Capecitabine 1000 mg/m² PO twice daily days 1-14, every 21 days 5
- Trastuzumab + other chemotherapy agents
- Trastuzumab + Lapatinib (1000 mg PO daily when combined with trastuzumab) 5
Timing consideration: If trastuzumab-based adjuvant treatment finished >12 months before recurrence, follow first-line recommendations; if ≤12 months, follow second-line recommendations 1.
HER2-Negative Disease
Preferred Adjuvant Regimens 3, 4, 7
Dose-dense AC → Paclitaxel every 2 weeks (with filgrastim support)
- Doxorubicin 60 mg/m² + Cyclophosphamide 600 mg/m² every 14 days × 4 cycles
- Followed by Paclitaxel 175 mg/m² every 14 days × 4 cycles
Dose-dense AC → Weekly Paclitaxel
- AC as above, followed by Paclitaxel 80 mg/m² weekly × 12 weeks
TC (Docetaxel + Cyclophosphamide)
Other Acceptable Regimens 3, 5
- TAC: Docetaxel 75 mg/m² + Doxorubicin 50 mg/m² + Cyclophosphamide 500 mg/m² every 21 days × 6 cycles (all with filgrastim)
- FEC → Docetaxel: Fluorouracil 500 mg/m² + Epirubicin 100 mg/m² + Cyclophosphamide 500 mg/m² × 3 cycles → Docetaxel × 3 cycles
- CMF: Cyclophosphamide (oral days 1-14) + Methotrexate + Fluorouracil (IV days 1 and 8) every 28 days × 6 cycles 4
Triple-Negative Breast Cancer (TNBC) Specific Options 7
- High-risk TNBC: Pembrolizumab + Carboplatin + Paclitaxel (neoadjuvant), followed by pembrolizumab + AC, then adjuvant pembrolizumab
- TNBC with residual disease after neoadjuvant therapy: Capecitabine 1000-1250 mg/m² PO twice daily days 1-14, every 21 days 7
- TNBC with germline BRCA1/2 mutations: Add olaparib 300 mg PO twice daily × 1 year if ≥pT2 or ≥pN1 after adjuvant chemotherapy, or residual disease after neoadjuvant therapy 7
Metastatic HER2-Negative Disease 5
Single agents:
- Paclitaxel 175 mg/m² every 21 days OR 80-90 mg/m² weekly
- Docetaxel 80-100 mg/m² every 21 days OR 35 mg/m² weekly
- Capecitabine 1000-1250 mg/m² PO twice daily days 1-14, every 21 days
- Gemcitabine 800-1200 mg/m² IV days 1,8,15 every 28 days
- Vinorelbine 25 mg/m² IV weekly
- Eribulin 1.4 mg/m² IV days 1 and 8, every 21 days
- Albumin-bound paclitaxel 100 mg/m² days 1,8,15 every 28 days OR 260 mg/m² every 21 days
Hormone Receptor-Positive Disease
Chemotherapy and endocrine therapy should be given sequentially, with endocrine therapy AFTER chemotherapy completion 5. Use same chemotherapy regimens as HER2-negative disease above.
For HR+/HER2+ metastatic disease: May consider endocrine therapy + trastuzumab or lapatinib in selected cases (low disease burden, long disease-free interval, contraindications to chemotherapy), though HER2-targeted therapy + chemotherapy remains preferred for most patients 1.
Dose Modifications
Neutropenia
- Grade 3-4 neutropenia: Hold chemotherapy until ANC >1000-1500/μL, then resume with dose reduction or add/continue G-CSF support
- Febrile neutropenia: Hold until resolution, resume with 20-25% dose reduction and mandatory G-CSF
- Dose-dense regimens require filgrastim 5 mcg/kg support 5, 7
Thrombocytopenia
- Platelets <75,000/μL: Hold chemotherapy
- Platelets 75,000-100,000/μL: Consider 25% dose reduction
- Resume when platelets >100,000/μL
Neuropathy
- Grade 2 (moderate symptoms): Reduce taxane dose by 20%
- Grade 3 (severe symptoms): Hold taxane until improvement to ≤Grade 1, then resume at 50% dose or switch to different agent
- Grade 4: Discontinue taxane permanently
Cardiac Toxicity (HER2-targeted therapy)
- LVEF decline to 40-49% or 10-15% absolute decrease from baseline: Hold trastuzumab/pertuzumab, repeat LVEF in 3 weeks
- LVEF <40%: Discontinue HER2-targeted therapy 5
Critical Considerations
Anthracycline cumulative dose limits: Doxorubicin ≤240 mg/m² (two-drug regimens) or ≤360 mg/m² (three-drug regimens); Epirubicin ≤600-720 mg/m² 4
Radiation timing: All chemotherapy (except CMF) should be completed before radiotherapy. CMF may be given concurrently with radiation 5.
Chemotherapy duration in metastatic setting: Continue for 4-6 months or to maximal response, then continue HER2-targeted therapy alone (if applicable) until progression 1.